Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Na-APR-1 (M74) + Alhydrogel + GLA-AF
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Na-APR-1 (M74) + Alhydrogel + GLA-AF is a hookworm vaccine candidate that combines a recombinant version of the Necator americanus aspartic protease-1 (Na-APR-1) with aluminum hydroxide adjuvant (Alhydrogel) and an aqueous formulation of Glucopyranosyl Lipid A (GLA-AF), a Toll-like receptor 4 (TLR4) agonist. The vaccine works by inducing neutralizing antibodies that block the enzymatic activity of Na-APR-1, a hemoglobinase that facilitates the ability of adult hookworms to parasitize the human intestine and feed on blood. The Na-APR-1 component is a catalytically inactive version of the wild-type hemoglobinase (M74 mutation) that is expressed in Nicotiana benthamiana tobacco plants using an Agrobacterium tumefaciens strain engineered to express the vaccine antigen. The addition of GLA-AF to Na-APR-1(M74)/Alhydrogel has been shown to result in higher levels of IgG antibodies against Na-APR-1(M74) compared to formulations without GLA-AF.
- Other names
- Na-APR-1 (M74)/Alhydrogel co-administered with GLA-AF
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Na-APR-1 (M74) + Alhydrogel + GLA-AF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Na-APR-1 (M74) + Alhydrogel + GLA-AF.